BCL2 and acute myeloid leukemia: We examined the MCL-1 and BCL-2 protein expression by IHC in two AML patients (#3-3570, #4-3072) harboring RAS mutation at the time of relapse on venetoclax combination trial, and found that MCL-1 expression increased in both patients at progression compared to baseline (Supplementary Table 4, Fig. 4f).